IGC Pharma (IGC) EBIAT (2016 - 2025)
Historic EBIAT for Pharma (IGC) over the last 17 years, with Q3 2025 value amounting to -$1.8 million.
- Pharma's EBIAT fell 605.71% to -$1.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.4 million, marking a year-over-year increase of 4871.51%. This contributed to the annual value of -$7.1 million for FY2025, which is 4522.31% up from last year.
- Per Pharma's latest filing, its EBIAT stood at -$1.8 million for Q3 2025, which was down 605.71% from -$1.6 million recorded in Q2 2025.
- Pharma's EBIAT's 5-year high stood at -$1.2 million during Q1 2025, with a 5-year trough of -$6.5 million in Q1 2022.
- For the 5-year period, Pharma's EBIAT averaged around -$2.8 million, with its median value being -$2.4 million (2021).
- Its EBIAT has fluctuated over the past 5 years, first plummeted by 16216.05% in 2021, then skyrocketed by 6727.5% in 2024.
- Pharma's EBIAT (Quarter) stood at -$2.4 million in 2021, then grew by 5.54% to -$2.2 million in 2022, then crashed by 148.51% to -$5.6 million in 2023, then soared by 67.28% to -$1.8 million in 2024, then rose by 0.44% to -$1.8 million in 2025.
- Its EBIAT stands at -$1.8 million for Q3 2025, versus -$1.6 million for Q2 2025 and -$1.2 million for Q1 2025.